(Q37571986)

21 August 2017

1 reference

title

Role of denosumab in breast cancer (English)

1 reference

21 August 2017

1 reference

Rupert Bartsch

1

1 reference

21 August 2017

Guenther G Steger

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1225-1233

1 reference

Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Second consensus on medical treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Bone resorption predicts for skeletal complications in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Different doses of pamidronate in patients with painful osteolytic bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Efficacy of ibandronate in metastatic bone disease: review of clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Human osteoclasts derive from CD14-positive monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Osteoprotegerin and rank ligand expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Clinical development of anti-RANKL therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Regulatory effects of osteoprotegerin on cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

Mechanisms of bone destruction in the development of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903146877

10.1517/14712590903146877

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference